We’re excited to announce our new brand identity to reflect a stronger, more focused, and modern representation of our team and company.
What started as an idea between friends in 2004, has come a long way to today with a fully remote, global team of 135+ (and counting). Larvol empowers healthcare and life sciences experts to improve their strategic decision-making by providing them with custom intelligence reports and SaaS solutions that are accurate, rapid, and expertly curated. Our four core products – Pulse, Conference, Omni, and Veri continue to add significant value to our industry and exemplify our commitment to providing outstanding products to our customers.
We’re excited to announce our new brand identity to reflect a stronger, more focused, and modern representation of our team and company in several ways:
Watch the video where Bruno talks about our brand-
A new logo demonstrating our focus on simplicity.
A relaunched website with an improved design, fresh look, and branding. Our website has been streamlined to find useful information quickly on products and features and provides an enhanced user experience. We’ve added to our team section to get to know the team behind it all. Get to know us more here. We’re adding new segmentation for our Blog and Top News sections to easier find information, articles, and news releases for the latest in healthcare and pharma spaces.
A new motto as mentioned earlier, “Semper Tigris” putting in the spotlight who we are at Larvol. The tiger has featured prominently internally as our “spirit animal” defining our razor-sharp focus, fearless approach to our work, and speed.
Our social media pages will undergo rebranding as well with added focus on unique content as well as updates and announcements. Don’t miss out on any action, follow us here: Facebook, Twitter, LinkedIn & Instagram.
Change is the only constant, but what our values including customer focus, innovation, and respect for people remain unchanged. We continue to create robust, scalable, high-quality intelligence tools for the pharmaceutical, life sciences, and healthcare industry and will be expanding our portfolio to include solutions focused on cancer data research.
We’re incredibly proud of the work we do at Larvol, and are thankful to all our stakeholders (customers, partners, and “Tigers” ) who have accompanied us in our growth. If you wish to know more connect with us at email@example.com.
The advent of precision oncology is marked by many new changes and improvements in diagnostic, prognostic and treatment methods for cancer patients. Researchers looking to bring new drugs to market are now also privy to a vast database of material from previously conducted studies thanks to a push forward in research collaborations and the creation of shared data hubs.
Well-established biomarkers in breast cancer today include BRCA1/BRCA2, estrogen and progesterone receptors as well as p53, which is the most studied biomarker in breast cancer. Let’s look at some of the biomarkers that are emerging in this space.